

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr David Brookes
Date of last notice	27 November 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	(a) Tarandi 1996 Pty Ltd <Dr DL Brookes Superfund> (Tarandi) (b) Dr David and Ms Elisabeth Brookes <Dahlbrook Family Trust> (Dahlbrook Family Trust) (c) Dr David and Ms Elizabeth <Dr DL Brookes Personal Superfund> (Brookes Superfund) Dr Brookes is within a class of beneficiaries of the Tarandi, Dahlbrook Family Trust and Brookes Superfund.
Date of Change	11 December 2025

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>Direct</p> <p>(a) 1,240,000 Ordinary Shares (b) 175,000 Options exercisable at \$0.07 each and expiring on 11.12.2025; (c) 1,500,000 Options exercisable at \$0.10 each and expiring on 9.7.2028 (50% vested on 9.7.25, 50% vesting 9.7.26).</p> <p>Indirect</p> <p><u>Tarandi</u> 6,956,669 Ordinary Shares;</p> <p><u>Dahlbrook Family Trust</u> (a) 1,666,667 Ordinary Shares; (b) 1,000,000 Options exercisable at \$0.10 each and expiring 9.7.2028 (50% vested on 9.7.25, 50% vesting 9.7.26); (c) 285,714 Options exercisable at \$0.07 each and expiring 11.12.2025</p> <p><u>Brookes Superfund</u> 471,429 Options exercisable at \$0.07 each and expiring 11.12.2025</p>
Class	Ordinary Shares and Options
Number acquired	Nil
Number disposed	932,143 Unlisted Options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	<p>Direct</p> <p>(a) 1,240,000 Ordinary Shares (b) 1,500,000 Options exercisable at \$0.10 each and expiring on 9.7.2028 (50% vested on 9.7.25, 50% vesting 9.7.26).</p> <p>Indirect</p> <p><u>Tarandi</u> 6,956,669 Ordinary Shares;</p> <p><u>Dahlbrook Family Trust</u> (a) 1,666,667 Ordinary Shares; (b) 1,000,000 Options exercisable at \$0.10 each and expiring 9.7.2028 (50% vested on 9.7.25, 50% vesting 9.7.26).</p>

+ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Unlisted Options
---	----------------------------

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dirk van Dissel
Date of last notice	27 November 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Candour Asset Management Pty Ltd, of which Mr van Dissel is a Director and Shareholder (Candour Asset) Candour Advisory Pty Ltd, of which Mr van Dissel is a Director and Shareholder (Candour Advisory)
Date of change	11 December 2025
No. of securities held prior to change	Candour Asset (a) 6,060,696 Ordinary Shares (b) 850,001 Unlisted Options expiring on 11.12.2025 and exercisable at \$0.07 each Candour Advisory 1,500,000 Unlisted Options expiring on 11.12.2025 and exercisable at \$0.07 each
Class	Ordinary Shares and Options
Number acquired	-

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	2,350,001 Unlisted Options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	Candour Asset 6,060,696 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Unlisted Options

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Michailidis
Date of last notice	24 December 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	John Michailidis & Helen Michailidis <Michailidis Family Account>
Date of change	11 December 2025
No. of securities held prior to change	(a) 1,299,999 Ordinary Shares (b) 250,000 Unlisted Options exercisable at \$0.07 each and expiring 11.12.2025 (c) 1,000,000 Unlisted Options exercisable at \$0.10 each and expiring 9.07.2028 (50% vested on 9.7.25, 50% vesting 9.7.26). (d) 359,640 Performance Rights
Class	Ordinary Shares, Options and Performance Rights
Number acquired	Nil
Number disposed	250,000 Unlisted Options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	(a) 1,299,999 Ordinary Shares (b) 1,000,000 Unlisted Options exercisable at \$0.10 each and expiring 9.07.2028 (50% vested on 9.7.25, 50% vesting 9.7.26); (c) 359,640 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Unlisted Options

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.